Avatar Trial Identifies New Treatment Route for Melanoma Patients

Melanoma accounts for approximately five percent of all skin cancer cases, yet it is responsible for nearly 75 percent of skin cancer-related deaths. The BRAF gene is frequently mutated in melanoma, leading to aberrant activation of an important growth pathway. Melanoma patients who receive treatment with targeted therapies that inhibit activated BRAF experience an initial… Read more »


The Bloody Business Of Tandem Duplications in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is the most common form of aggressive hematologic malignancy affecting adults. AML is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is a relatively rare disease, however its incidence increases with age, thus… Read more »


Syngenic Models Take Center Stage In Immunotherapy

Syngenic models were developed over 50 years ago as early in vivo models for oncology drug development, consisting of allograft of murine tumor cells in hosts with a fully functional immune system. After an initial phase of great popularity they drifted out of the drug discovery landscape with the shift towards therapies directed against human… Read more »


Fatty Liver Disease And The Need for New Translational Models

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in developed countries, occurring when fat is deposited in the liver, independently from excessive alcohol use. NAFLD affects approximately 20% of the United States population and 25-30% of people in the UK, according to a recent study using the National Health and Nutrition Examination… Read more »